Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5584437 | Experimental and Molecular Pathology | 2017 | 31 Pages |
Abstract
In this limited comparison study, this commercial next generation sequencing based-targeted genomic profiling showed a high concordance rate with conventional methods for the 3 genetic alterations and identified mutations expected for the type of glioma. While it may not be feasible to exhaustively independently validate a commercial genomic profiling assay, examination of a few markers provides some reassurance of its robustness. While potential targeted drugs are recommended based on genetic alterations, to date most targeted therapies have failed in glioblasomas so the usefulness of such recommendations will increase with development of novel and efficacious drugs.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Masoud Movassaghi, Maryam Shabihkhani, Seyed A. Hojat, Ryan R. Williams, Lawrance K. Chung, Kyuseok Im, Gregory M. Lucey, Bowen Wei, Sergey Mareninov, Michael W. Wang, Denise W. Ng, Randy S. Tashjian, Shino Magaki, Mari Perez-Rosendahl, Isaac Yang,